RETINSIGHT GMBH

RetInSight is a MedTech company which was founded in 2020 as a spin-off from the Medical University of Vienna, with the goal to revolutionise eye care and improve accessibility to screening at-risk patients for frequent retinal diseases like neovascular age-related macular degeneration (nAMD), geographic atrophy (GA), diabetic macular edema (DME), and retinal vein occlusion (RVO).

Role in I-SCREEN

Since the foundation of RetInSight in 2020, we have established ourselves as a leading AI software manufacturer in the ophthalmic market. As evidenced by the Centre of AI Reading Excellence (cAIre), the CE/MDR approved RetInSight Fluid Monitor and the novel GA Monitor, our comprehensive suite of solutions offers a unique blend of advanced AI-driven technologies and a cloud-based platform, catering to the diverse needs of clinical trial support, therapeutic monitoring and diagnostic screening for exudative and degenerative retinal diseases. RetInSight will provide a cloud-based data collection platform, cAIre Direct, for the duration of the project as well as develop a screening algorithm for detection of functional dry AMD in a community-based population. The developed model will identify OCT volumes with functional atrophic AMD. Furthermore, RetInSight’s Fluid and GA Monitors will be used as part of the Sudetes and Apennines clinical studies to provide deep clinical insight of disease activity of the patients.

Team Members